

SKYEPHARMA PLC  
Form 6-K  
April 18, 2007

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of April, 2007

SkyePharma PLC

---

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

---

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

**CIRCULAR POSTED TODAY TO SHAREHOLDERS**

## Edgar Filing: SKYEPHARMA PLC - Form 6-K

LONDON, UK, APRIL 18, 2007-- SkyePharma PLC (LSE: SKP; NASDAQ: SKYE) announces that a Circular containing details of a new long-term incentive plan (the "LTIP") will today be posted to shareholders.

The Circular includes a notice convening an Extraordinary General Meeting to be held at 11.00 a.m. on 4 May 2007 at the offices of Fasken Martineau Stringer Saul LLP, 4th Floor, 17 Hanover Square, London, W1S 1HU at which a resolution will be proposed to approve the LTIP.

### **For further information please contact:**

#### **SkyePharma PLC**

**+44 207 491 1777**

Frank Condella, Chief Executive Officer  
Ken Cunningham, Chief Operating Officer  
Peter Grant, Finance Director

#### **Financial Dynamics**

**+44 207 7831 3113**

David Yates  
Deborah Scott

#### **The Trout Group**

**+ 1 617 583 1308**

Seth Lewis

### **About SkyePharma PLC**

Using its proprietary drug delivery technologies, SkyePharma develops new formulations of known molecules to provide a clinical advantage and life-cycle extension. The Company has nine approved products in the areas of oral, inhalation and topical delivery that are marketed throughout the world by leading pharmaceutical companies. For more information, visit

[www.skyepharma.com](http://www.skyepharma.com).

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**SkyePharma PLC**

By: /s/ John Murphy

Name: John Murphy  
Title: Company Secretary

Date: April 18, 2007